Argos Therapeutics, Inc.
(Other OTC/NBB : ARGS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.29%300.261.4%$596.56m
AMGNAmgen, Inc.
0.15%233.771.3%$511.86m
GILDGilead Sciences, Inc.
1.74%67.081.0%$364.16m
REGNRegeneron Pharmaceuticals, Inc.
1.06%372.262.6%$296.10m
VRTXVertex Pharmaceuticals, Inc.
0.08%223.251.9%$267.50m
ILMNIllumina, Inc.
2.08%326.473.5%$239.80m
ALXNAlexion Pharmaceuticals, Inc.
6.02%113.892.0%$195.68m
ARWRArrowhead Pharmaceuticals, Inc.
2.66%67.2712.0%$195.66m
EXASEXACT Sciences Corp.
3.15%86.2424.0%$182.79m
CLVSClovis Oncology, Inc.
8.47%9.6114.7%$181.81m
SRPTSarepta Therapeutics, Inc.
-0.46%109.4614.6%$145.45m
AAgilent Technologies, Inc.
0.88%82.251.6%$143.48m
NBIXNeurocrine Biosciences, Inc.
0.28%116.815.0%$128.05m
BMRNBioMarin Pharmaceutical, Inc.
-0.20%79.924.3%$126.79m
SGENSeattle Genetics, Inc.
0.29%117.506.1%$126.10m

Company Profile

Argos Therapeutics, Inc. is a biopharmaceutical company, which engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Ralph Steinman on May 8, 1997 and is headquartered in Durham, NC.